V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 330010749 | 330005560 | 0 | 13.3 | Palliative (P) | 2017-07-31 | 2017-08-22 | Ifosfamide | 02 | N | 330021317 | EDP |
| 330010750 | 330005561 | null | 60 | Curative (C) | 2016-01-01 | 2016-01-02 | BUSULFAN + CYCLO | 2 | null | 330021319 | PEMBROLIZUMAB |
| 330010752 | 330005565 | null | 83.2 | Palliative (P) | 2015-09-06 | 2016-06-17 | Carboplatin + Doxorubicin | 02 | N | 330021342 | CLADRIBINE |
| 330010753 | 330009037 | 1.74 | 79.1 | Curative (C) | 2017-08-02 | 2017-08-02 | ALL UKALL2011 TRIAL | Y | N | 330021349 | CLADRIBINE |
| 330010754 | 330012867 | 1.71 | 49 | Palliative (P) | 2015-04-26 | 2015-05-06 | BCG Intravesical | 02 | N | 330021363 | FLUOROURACIL + MITOMYCIN + RT |
| 330010755 | 330012867 | 1.6 | 60.8 | Palliative (P) | 2017-06-04 | 2017-11-15 | EDP + MITOTANE | 01 | N | 330021363 | DOXORUBICIN + GEMCITABINE |
| 330010756 | 330005571 | null | 51 | Unknown (U) | 2016-06-06 | 2016-12-27 | CYTARABINE | 02 | N | 330021390 | BLINATUMOMAB |
| 330010758 | 330005575 | 1.79 | 75 | Curative (C) | 2014-10-19 | 2015-08-13 | BEP 5 Day | N | N | 330021428 | CARBO + THIOTEPA + TOPOTECAN |
| 330010759 | 330010907 | 1.93 | 76.4 | Palliative (P) | 2015-07-06 | 2015-07-06 | Doxorubicin + Methotrexate | 02 | N | 330021489 | MAP + MIFAMURTIDE |
| 330010760 | 330005581 | 1.6 | 76.7 | Curative (C) | 2016-08-23 | 2016-08-30 | CTD | 2 | N | 330021489 | CETUXIMAB + CISPLATIN + FU |
| 330010761 | 330005583 | 1.68 | 93.499 | Disease modification (D) | 2018-01-13 | 2018-01-16 | VINCRISTINE | 02 | N | 330021531 | DACTINOMYCIN + VINCRISTINE |
| 330010762 | 330005585 | 0 | 82.1 | Palliative (P) | 2016-07-20 | 2016-07-27 | AML LI-1 Trial | N | N | 330021553 | CARBOPLATIN + CETUXIMAB + FU |
| 330010763 | 330005585 | 1.77 | 70.2 | null | 2014-07-30 | 2014-08-04 | MAP + MIFAMURTIDE | 01 | N | 330021553 | FCR |
| 330010764 | 330005586 | 1.73 | 52 | Palliative (P) | null | 2018-01-06 | CISPLATIN + DACTINOMYCIN + ETOPOSIDE + METHOTREXATE | N | null | 330021574 | DACTINOMYCIN + VINCRISTINE |
| 330010765 | 330005588 | 1.58 | 62.25 | Palliative (P) | 2018-06-07 | 2018-06-07 | MAP + MIFAMURTIDE | 2 | N | 330021591 | DOXORUBICIN + GEMCITABINE |
| 330010766 | 330005590 | null | 68.9 | Neo-adjuvant (N) | 2013-08-11 | 2013-08-30 | ADE 8+3+5 | N | N | 330021602 | BEP |
| 330010767 | 330005596 | 1.77 | 19.5 | Palliative (P) | 2017-12-18 | 2018-02-20 | Brentuximab | N | N | 330021634 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 330010768 | 330005598 | 1.8 | 56 | Palliative (P) | 2015-10-21 | 2016-02-12 | Capecitabine + Cisplatin | 02 | N | 330021653 | CAPECITABINE + CARBOPLATIN |
| 330010769 | 330005602 | null | 58.2 | Adjuvant (A) | 2017-08-13 | 2017-08-13 | VINCRISTINE | N | N | 330021660 | BEP |
| 330010770 | 330005603 | null | 57.2 | Palliative (P) | 2014-07-12 | 2014-12-31 | Ixazomib + Lenalidomide | N | null | 330021667 | CISPLATIN + ETOPOSIDE + PACLITAXEL |
| 330010771 | 330010918 | 0.96 | 66.2 | Palliative (P) | 2015-09-12 | 2015-10-17 | LIPOSOMAL DAUNORUBICIN | Y | N | 330021674 | CVP |
| 330010772 | 330005605 | 1.75 | 51.45 | Curative (C) | 2013-09-14 | 2013-12-09 | UKALL14- Ph 1 Induction | Y | null | 330021687 | CARBOPLATIN + CETUXIMAB + FU |
| 330010773 | 330009060 | 0 | 54 | Curative (C) | 2016-10-08 | 2016-10-09 | Mitotane 5.5 - 10g | 2 | N | 330021690 | CISPLATIN + VINORELBINE |
| 330010774 | 330005606 | 1.79 | 50.6 | Palliative (P) | 2016-06-09 | 2016-06-14 | Cetuximab + CISPLATIN + FLUOROURACIL | N | N | 330021693 | IFOSFAMIDE |
| 330010775 | 330005608 | null | null | Curative (C) | 2015-03-06 | 2015-09-11 | ETOPOSIDE + IFOSFAMIDE + MTX | 02 | N | 330021695 | CYTARABINE IT + METHOTREXATE |
| 330010776 | 330009061 | null | 92.1 | Curative (C) | 2017-05-04 | 2017-05-31 | STS Rhabdomyosarcoma RMS 2005 VA | null | null | 330021695 | IVA |
| 330010777 | 330005611 | 1.16 | 136 | Curative (C) | 2014-08-07 | 2014-08-07 | BLEOMYCIN + CISPLATIN + ETOPOSIDE | N | N | 330021734 | ALEMTUZUMAB + FLUDARABINE + MELPHALAN |
| 330010778 | 330005617 | null | 15.7 | Palliative (P) | 2017-07-23 | 2017-12-06 | AXI-STS TRIAL | null | N | 330021739 | HYDROXYCARBAMIDE |
| 330010779 | 330005618 | 1.7 | 53.8 | Palliative (P) | 2018-04-05 | 2018-04-07 | CAPECITABINE + CARBOPLATIN + Cetuximab | N | N | 330021746 | FLUOROURACIL + MITOMYCIN + RT |
| 330010780 | 330005619 | 0 | 75.4 | Curative (C) | 2016-11-30 | 2017-01-25 | EDP + MITOTANE | N | N | 330021811 | RUXOLITINIB |
| 330010781 | 330005620 | null | 55.9 | Palliative (P) | null | 2015-03-28 | EMA/CO | N | N | 330021850 | DACTINOMYCIN + VINCRISTINE |
| 330010782 | 330011945 | 1.56 | 92.2 | null | 2017-06-19 | 2017-07-11 | Capecitabine + Cisplatin | N | N | 330021874 | AML18 TRIAL |
| 330010783 | 330009067 | 0 | 0 | Adjuvant (A) | 2017-11-29 | 2017-11-29 | Nelarabine | 02 | N | 330021899 | DASATINIB |
| 330010784 | 330005623 | 1.78 | 75.5 | null | 2014-10-15 | 2014-11-09 | Capecitabine (21days) + Carboplatin | N | null | 330021935 | UKALL2014 |
| 330010785 | 330005625 | 1.82 | null | Palliative (P) | 2013-11-08 | 2013-11-08 | CISPLATIN + METHOTREXATE + VINCRISTINE | N | null | 330021970 | CAPECITABINE |
| 330010786 | 330009069 | 1.76 | null | Palliative (P) | 2015-02-15 | 2015-02-15 | Cisplatin + Vinorelbine (IV) | N | N | 330021973 | BLEOMYCIN + CARBOPLATIN + ETOPOSIDE |
| 330010787 | 330009070 | null | 73.9 | Curative (C) | null | 2015-07-12 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | null | N | 330022010 | CYTARABINE |
| 330010788 | 330005629 | 0 | 84.5 | Disease modification (D) | 2018-06-15 | 2018-06-16 | CYCLOPHOSPHAMIDE | N | N | 330022010 | IFOSFAMIDE + PACLITAXEL |
| 330010789 | 330012870 | 1.15 | 69 | Disease modification (D) | 2017-02-17 | 2017-02-21 | ALEMTUZUMAB + BUSULFAN + FLUDARABINE | 02 | N | 330022051 | CYTARABINE |
| 330010790 | 330009072 | 1.67 | 52 | Palliative (P) | 2017-08-13 | 2017-08-14 | Cyclophosphamide + Vincristine | N | N | 330022092 | DOXORUBICIN + METHOTREXATE |
| 330010791 | 330005632 | 0.9 | 14.65 | null | 2013-09-04 | 2013-11-12 | CNS LGG 2004 03 vinc weekly+ carbo | 01 | N | 330022105 | HYDROXYCARBAMIDE |
| 330010792 | 330005634 | 1.55 | 61.1 | null | 2016-01-08 | 2016-01-12 | Mitotane 2g | 02 | N | 330022131 | DACTINOMYCIN |
| 330010793 | 330005636 | 1.82 | 80 | Palliative (P) | 2018-08-11 | 2018-08-31 | Bendamustine +/- Prednisolone | 02 | N | 330022152 | DE-ESCALATE TRIAL |
| 330010794 | 330005640 | 1.52 | 60 | Curative (C) | 2014-10-15 | 2014-10-19 | Carboplatin + Thiotepa + Topotecan | 2 | N | 330022219 | CASPS TRIAL |
| 330010795 | 330005641 | 1.7 | 80.1 | Curative (C) | 2017-10-09 | 2017-10-25 | IBRUTINIB | N | N | 330022242 | CARBOPLATIN + CETUXIMAB + FU |
| 330010797 | 330005647 | null | 70 | Palliative (P) | 2018-03-06 | 2018-12-26 | Cyclophosphamide High Dose | N | N | 330022274 | ALEMTUZUMAB |
| 330010798 | 330005649 | null | 110.6 | Palliative (P) | 2013-10-29 | 2013-11-13 | CARBOPLATIN + DOCETAXEL + FLUOROURACIL | N | null | 330022302 | IPILIMUMAB |
| 330010799 | 330005651 | 0 | 120.4 | Disease modification (D) | 2018-05-21 | 2018-05-21 | Cyclophosphamide + Vincristine | N | N | 330022321 | ETOPOSIDE + IFOSFAMIDE + MTX |
| 330010800 | 330005651 | 1.55 | 50.7 | Palliative (P) | 2015-09-20 | 2015-09-20 | Bendamustine +/- Prednisolone | N | N | 330022321 | CLADRIBINE |
| 330010801 | 330009085 | 1.73 | 30.4 | Palliative (P) | null | 2014-05-21 | Cyclophosphamide High Dose | 02 | null | 330022355 | ALDESLEUKIN |